Previous close | 906.54 |
Open | 912.68 |
Bid | 889.93 x 100 |
Ask | 891.41 x 100 |
Day's range | 877.13 - 915.00 |
52-week range | 684.81 - 998.33 |
Volume | |
Avg. volume | 466,462 |
Market cap | 97.763B |
Beta (5Y monthly) | 0.14 |
PE ratio (TTM) | 25.64 |
EPS (TTM) | 34.74 |
Earnings date | 02 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 1,049.15 |
EXEL vs. REGN: Which Stock Is the Better Value Option?
Regeneron (REGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AbbVie said on Thursday its drug, Rinvoq, for treating a type of inflammatory skin condition was found to be more effective than Regeneron Pharmaceuticals and Sanofi's Dupixent in a late-stage head-to-head study. Rinvoq helped 19.9% of patients simultaneously achieve near-complete skin clearance with a no-to-little itch after 16 weeks of treatment, compared with 8.9% of patients treated with Dupixent, the study showed. The study is the first head-to-head trial in adults and adolescents with moderate-to-severe atopic dermatitis and had shown an inadequate response to systemic therapy, AbbVie said.